Integrated Biopharma, Inc. INBP
OTC PK
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -19.28% | -8.83% | -0.06% | 4.72% | 8.02% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -19.28% | -8.83% | -0.06% | 4.72% | 8.02% |
| Cost of Revenue | -11.72% | -3.23% | 2.07% | 3.47% | 5.08% |
| Gross Profit | -85.62% | -58.32% | -19.83% | 17.79% | 43.20% |
| SG&A Expenses | -1.04% | -1.58% | -3.70% | -3.06% | -2.50% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -11.00% | -3.12% | 1.66% | 3.00% | 4.53% |
| Operating Income | -233.91% | -168.03% | -60.18% | 112.96% | 704.78% |
| Income Before Tax | -224.30% | -159.44% | -52.23% | 114.43% | 669.40% |
| Income Tax Expenses | -77.75% | -14.51% | 70.97% | 178.87% | 703.85% |
| Earnings from Continuing Operations | -451.73% | -231.90% | -122.20% | 56.28% | 621.43% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -451.73% | -231.90% | -122.20% | 56.28% | 621.43% |
| EBIT | -233.91% | -168.03% | -60.18% | 112.96% | 704.78% |
| EBITDA | -203.17% | -144.22% | -50.14% | 80.45% | 319.00% |
| EPS Basic | -441.04% | -228.19% | -119.81% | 55.24% | 624.32% |
| Normalized Basic EPS | -220.52% | -157.73% | -55.19% | 109.36% | 657.14% |
| EPS Diluted | -476.32% | -249.88% | -138.64% | 53.15% | 618.92% |
| Normalized Diluted EPS | -222.84% | -159.26% | -55.81% | 113.33% | 700.00% |
| Average Basic Shares Outstanding | 2.52% | 2.58% | 2.12% | 1.45% | 0.77% |
| Average Diluted Shares Outstanding | 0.42% | -0.02% | 0.98% | 2.17% | 2.11% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |